Life Science Bio-Tech (India) Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 28-12-2024
- Paid Up Capital ₹ 0.10 M
as on 28-12-2024
- Company Age 22 Year, 8 Months
- Last Filing with ROC 31 Mar 2020
- Open Charges ₹ 6.50 M
as on 28-12-2024
- Satisfied Charges ₹ 0.45 M
as on 28-12-2024
- Revenue 18.43%
(FY 2019)
- Profit 32.26%
(FY 2019)
- Ebitda 2.21%
(FY 2019)
- Net Worth 1.04%
(FY 2019)
- Total Assets -4.60%
(FY 2019)
About Life Science Bio-Tech (India)
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹6.50 M. The company has closed loans amounting to ₹0.45 M, as per Ministry of Corporate Affairs (MCA) records.
Sudhakar Zaladanki, Hima Zaladhanki, and Zaladhanki Asha serve as directors at the Company.
- CIN/LLPIN
U24239TG2002PTC038810
- Company No.
038810
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Apr 2002
- Date of AGM
31 Dec 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Life Science Bio-Tech (India)?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sudhakar Zaladanki  | Director | 18-Apr-2002 | Current |
| Hima Zaladhanki | Director | 18-Apr-2002 | Current |
| Zaladhanki Asha | Director | 06-Nov-2023 | Current |
Financial Performance of Life Science Bio-Tech (India).
Life Science Bio-Tech (India) Private Limited, for the financial year ended 2019, experienced significant growth in revenue, with a 18.43% increase. The company also saw a substantial improvement in profitability, with a 32.26% increase in profit. The company's net worth moved up by a moderate rise of 1.04%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Life Science Bio-Tech (India)?
In 2019, Life Science Bio-Tech (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Karur Vysya Bank Limited Creation Date: 17 May 2010 | ₹6.50 M | Open |
Uco Bank Creation Date: 16 Jun 2005 | ₹0.20 M | Satisfied |
Uco Bank Creation Date: 18 Mar 2003 | ₹0.25 M | Satisfied |
How Many Employees Work at Life Science Bio-Tech (India)?
Unlock and access historical data on people associated with Life Science Bio-Tech (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Life Science Bio-Tech (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Life Science Bio-Tech (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
